Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1600132/000160013221000048/blph-20211007x8k.htm
March 2024
January 2024
January 2024
January 2024
December 2023
November 2023
October 2023
October 2023
August 2023
July 2023
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1600132/000160013221000048/blph-20211007x8k.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Bellerophon Therapeutics, Inc..
Bellerophon Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:
Financial Statements, Disclosures and Schedules
Inside this 8-K Corporate News
Ticker: BLPHEvents:
CIK: 1600132
Form Type: 8-K Corporate News
Accession Number: 0001600132-21-000048
Submitted to the SEC: Tue Oct 12 2021 4:59:25 PM EST
Accepted by the SEC: Tue Oct 12 2021
Period: Thursday, October 7, 2021
Industry: Pharmaceutical Preparations